Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
| Revenue (TTM) | $4.62T |
| Gross Profit (TTM) | $2.98T |
| EBITDA | $1.25T |
| Operating Margin | 16.50% |
| Return on Equity | -2.26% |
| Return on Assets | 2.69% |
| Revenue/Share (TTM) | $1462.74 |
| Book Value | $15.18 |
| Price-to-Book | 1.25 |
| Price-to-Sales (TTM) | 0.01 |
| EV/Revenue | 3.018 |
| EV/EBITDA | 23.74 |
| Quarterly Earnings Growth (YoY) | -9.80% |
| Quarterly Revenue Growth (YoY) | 10.20% |
| Shares Outstanding | $3.19B |
| Float | $3.16B |
| % Insiders | 0.06% |
| % Institutions | 3.31% |
Volatility is currently contracting
Roche on Wednesday said it was proposing Christoph Weber, the former CEO of Takeda Pharmaceuticals , for election to the Swiss company's board of directors at its AGM next March.
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social Responsibility (CSR) partners as part of the company's ongoing commitment to supporting climate-resilient health systems in low- and middle-income countries around the world and aligned with the company's purpose of better health for people, brighter future for the world. As climate change, extreme weather events and shifting.
Dr Reddy's Laboratories said on Friday it signed a deal with Takeda Pharmaceutical Company for the promotion and distribution of the Qdenga dengue vaccine in India.
Takeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
SIG, TAK and TX made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 14th, 2026.
TX, HPQ and TAK made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 14th, 2026.
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque ps.
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine o.
The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TAK and any ticker you trade — then tracks every position and per-strategy win rate.
